SC 13G/A - Neurogene Inc. (0001404644) (Subject)

SC 13G/A - Neurogene Inc. (0001404644) (Subject)

SC 13G/A - Neurogene Inc. (0001404644) (Subject)

SC 13G - Neurogene Inc. (0001404644) (Subject)

SC 13G - Neurogene Inc. (0001404644) (Subject)

SC 13G - Neurogene Inc. (0001404644) (Subject)

SC 13G - Neurogene Inc. (0001404644) (Subject)

BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00

Robert W. Baird initiated coverage of Neurogene with a rating of Outperform and set a new price target of $54.00

Leerink Partners initiated coverage of Neurogene with a rating of Outperform and set a new price target of $46.00

William Blair initiated coverage of Neurogene with a rating of Outperform and set a new price target of $61.00

8-K - Neurogene Inc. (0001404644) (Filer)

10-Q - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

NT 10-Q - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

10-Q - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

8-K - Neurogene Inc. (0001404644) (Filer)

Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett syndrome Neurogene to advance NGN-401 at 1E15 vg dose Expects to provide an update on registrational trial design in first half of 2025 Strong cash position provides runway into the second half of 2027 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2024 financial results and highlighted recent corporate updates. "The recently announced interim data from participants dosed with 1E15 vg in the NGN-401 clinical trial showed consistent imp

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response tha

All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration

Financing included participation from top-tier healthcare funds Proceeds expected to fund Company into the second half of 2027 Company to host webcast to review interim clinical data from Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome on November 11 at 4:30 p.m. ET Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $200 million to Neurogene, before placement agent fees

Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking

NGN-401 gene therapy for Rett syndrome received RMAT designation from FDA based on preliminary clinical evidence indicating the potential to address unmet medical needs NGN-401 selected for FDA START Program, also designed to accelerate development Interim NGN-401 efficacy data from Cohort 1 remains on track for 4Q:24 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates. "We are pleased that NGN-401 gene therapy for Rett syndrome received RMAT designation, in addition to the

Designation based on preliminary clinical evidence from ongoing NGN-401 clinical trial that shows potential to address unmet medical needs in Rett syndrome RMAT designation provides an opportunity for an Accelerated Approval pathway under the 21st Century Cures Act, and is in addition to NGN-401's selection by the FDA for the START Pilot Program Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that NGN-401 received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Rett syndrom

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the BMO 2024 Genetic Medicines Summit. Format: Management will participate in the panel, "Gene Therapy in Rare Disease: Unmet Need + Lack of Alternatives = Commercial Viability?" and participate in investor meetings Date: Tuesday, July 9 at 8:30 a.m. ET About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and t

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Neurogene will be added to the Russell 3000® Index, effective at the open of U.S. equity markets today, Monday, July 1, 2024. The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30, 2024, ranking them by total market capitalization. Neurogene's membership in the U.S. all-cap Russell 3000® Index will remain in place for one year. Neurogene has also been added to the Russell 2000® Index and the Russell Microcap® Index. "We are proud of all that we have

High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profile Interim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND Summit Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024. The Company also provided an update on interim safety data on the first three p

BMO Capital analyst Keith Tapper initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $65.

Gainers Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million. Neurogene (NASDAQ:NGNE) shares rose 31.92% to $40.0. The company's market cap stands at $519.2 million. Geovax Labs (NASDAQ:GOVX) shares rose 28.94% to $2.45. The company's market cap stands at $6.1 million. SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 24.03% to $3.2. The market value of their outstanding shares is at $29.5 million. Trevena (NASDAQ:TRVN) stock rose 23.33% to $0.44. The market value of their outstanding shares is at $8.0 million. Molecular Partners (NASDAQ:MOLN) stock rose 22.23% to $9.73. The company's

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.

Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Quantum shares dipped 44.5% to $0.43 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Reliance Global Group, Inc. (NASDAQ:RELI) shares jumped 350% to $1.00 after the company issued an update on the pending acquisition of Spetner Associates. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 166% to $0.3930 after jumping 30% on Monday. Actelis Networks, Inc. (NASDAQ:ASNS) climbed 80.9% to $2.08 after the company announced a partnership with Carahsoft Tech

High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profileInterim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND SummitNeurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024. The Company also provided an update on interim safety data on the first three patients

Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $54.

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.

All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration

Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking